INT127022

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 43
Total Number 44
Disease Relevance 28.29
Pain Relevance 12.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
osteoblasts 9
neutrophils 3
cardiovascular system 2
synovial fluid 1
macrophages 1
Lts1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammatory mediators 22 100.00 Very High Very High Very High
Osteoarthritis 2178 99.84 Very High Very High Very High
Inflammation 313 99.38 Very High Very High Very High
antagonist 38 98.36 Very High Very High Very High
fibrosis 20 97.44 Very High Very High Very High
Pain 185 94.96 High High
cINOD 229 94.88 High High
Inflammatory response 26 94.16 High High
COX-2 inhibitor 85 93.36 High High
Angina 18 87.68 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 420 100.00 Very High Very High Very High
Osteoarthritis 2200 99.84 Very High Very High Very High
Targeted Disruption 38 99.70 Very High Very High Very High
Hypersensitivity 2 99.56 Very High Very High Very High
Acute Coronary Syndrome 81 99.52 Very High Very High Very High
Cardiovascular Disease 45 99.50 Very High Very High Very High
Hypercalcemia 100 99.48 Very High Very High Very High
Asthma 245 98.52 Very High Very High Very High
Fibrosis 20 97.44 Very High Very High Very High
Hyperplasia 30 96.36 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Not surprisingly, HTS was able to detect all transcripts in both Pet-1 wild-type and knockout mice, whereas LTS detected only 20 of 32 possible transcripts, with 12 of those 20 detected in only one or the other genotype.
Gene_expression (detected) of LTS associated with targeted disruption
1) Confidence 0.23 Published 2010 Journal Nucleic Acids Research Section Body Doc Link PMC2879535 Disease Relevance 0.10 Pain Relevance 0
The LTS and HTS approaches produce comparable estimates of editing frequencies by site.
Gene_expression (approaches) of LTS
2) Confidence 0.23 Published 2010 Journal Nucleic Acids Research Section Body Doc Link PMC2879535 Disease Relevance 0.17 Pain Relevance 0
Our LTS results are consistent with many previous studies in being able to detect only a subset of all theoretically possible transcripts (15).
Gene_expression (results) of LTS
3) Confidence 0.23 Published 2010 Journal Nucleic Acids Research Section Body Doc Link PMC2879535 Disease Relevance 0.09 Pain Relevance 0
Comparison of results obtained by LTS and HTS
Gene_expression (obtained) of LTS
4) Confidence 0.23 Published 2010 Journal Nucleic Acids Research Section Body Doc Link PMC2879535 Disease Relevance 0.07 Pain Relevance 0
This might be explained by the effects of montelukast on the cysLTs production, discussed above.
Gene_expression (production) of cysLTs
5) Confidence 0.14 Published 2006 Journal Respir Res Section Body Doc Link PMC1456970 Disease Relevance 0.91 Pain Relevance 0.22
During recent years, combined 5-LOX/COX-inhibition, interfering with the biosynthesis of both prostaglandins and leukotrienes (LTs), has emerged as a possibility to avoid side effects related to COX-inhibition.
Gene_expression (biosynthesis) of LTs
6) Confidence 0.12 Published 2005 Journal Biochem. Pharmacol. Section Abstract Doc Link 15894291 Disease Relevance 0.40 Pain Relevance 0.52
Possible reasons for this are not clear, since this drug inhibits cys-LT1 receptors which should not affect the synthesis of cysLTs.
Gene_expression (synthesis) of cysLTs
7) Confidence 0.12 Published 2006 Journal Respir Res Section Body Doc Link PMC1456970 Disease Relevance 0.22 Pain Relevance 0
However, recent evidence suggests that montelukast may have an inhibitory effect on cysLTs synthesis through an inhibitory effect on 5'-lipoxygenase, an essential enzyme in the biosynthesis of leukotrienes in addition to its antagonism of its receptors [17].
Gene_expression (synthesis) of cysLTs
8) Confidence 0.12 Published 2006 Journal Respir Res Section Body Doc Link PMC1456970 Disease Relevance 0.21 Pain Relevance 0
Csoma et al. have reported that cysLTs were detectable in all 13 children with moderate to severe persistent asthma who were included in their study, but no influence of montelukast was investigated since this drug was not given to any of the patients [6].
Gene_expression (detectable) of cysLTs associated with asthma
9) Confidence 0.12 Published 2006 Journal Respir Res Section Body Doc Link PMC1456970 Disease Relevance 0.33 Pain Relevance 0
The first committed step in the synthesis of LTs is the oxidation of AA by 5-LO, and the integral membrane protein FLAP is an essential partner of 5-LO for this process [44].
Gene_expression (synthesis) of LTs
10) Confidence 0.12 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.44 Pain Relevance 0.04
In addition, cysLTs can be detected in EBC, with elevated levels reported in adults and children with asthma [5,6].
Gene_expression (detected) of cysLTs associated with asthma
11) Confidence 0.11 Published 2006 Journal Respir Res Section Body Doc Link PMC1456970 Disease Relevance 1.26 Pain Relevance 0.20
We have shown that exhaled cysLTs are detectable in children with moderate to persistent asthma with significantly lower concentrations in children who were additionally treated with montelukast compared to children who were not treated with montelukast.
Gene_expression (detectable) of cysLTs associated with asthma
12) Confidence 0.11 Published 2006 Journal Respir Res Section Body Doc Link PMC1456970 Disease Relevance 0.34 Pain Relevance 0
The LT synthesis inhibitor blocks key steps in the biosynthetic pathway (either 5-LO or 5-LO activating protein—FLAP) to inhibit production of both Cys-LTs and LTB4, whereas the LTRAs selectively block the CysLT1 receptor on target cells.
Gene_expression (production) of LTs
13) Confidence 0.10 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.61 Pain Relevance 0.04
Zileuton (ZIL) is the only marketed drug with a specific effect on Cys-LTs synthesis through the inhibition of the 5-LO enzyme, administered orally four times daily (QID).
Gene_expression (synthesis) of LTs
14) Confidence 0.10 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.49 Pain Relevance 0.03
In order to regulate the effects of Cys-LTs pharmacologically, two general approaches have been used with success: LTs synthesis inhibition and LTs receptor antagonism.
Gene_expression (antagonism) of LTs receptor
15) Confidence 0.10 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.85 Pain Relevance 0.07
In order to regulate the effects of Cys-LTs pharmacologically, two general approaches have been used with success: LTs synthesis inhibition and LTs receptor antagonism.
Gene_expression (synthesis) of LTs
16) Confidence 0.09 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.85 Pain Relevance 0.07
Recently have been announced the results of Phase 2 trials in acute coronary syndrome (ACS) investigating VIA-2291, a selective and reversible inhibitor of 5-LO, a key enzyme in LTs biosynthesis.
Gene_expression (biosynthesis) of LTs associated with acute coronary syndrome
17) Confidence 0.09 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 1.11 Pain Relevance 0.17
LTs have not been perceived as promoters of CVD until recently, despite actions of LTs in the cardiovascular system (CVS).
Gene_expression (actions) of LTs in cardiovascular system associated with cardiovascular disease
18) Confidence 0.09 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.88 Pain Relevance 0.05
In order to regulate the effects of Cys-LTs pharmacologically, two general approaches have been used with success: LTs synthesis inhibition and LTs receptor antagonism.
Gene_expression (antagonism) of LTs
19) Confidence 0.09 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.89 Pain Relevance 0.08
LTs are potent inflammatory mediators synthesized within the cardiovascular system through the 5-LO pathway of AA metabolism.
Gene_expression (synthesized) of LTs in cardiovascular system associated with inflammatory mediators
20) Confidence 0.08 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2817543 Disease Relevance 0.92 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox